Pular para o conteúdo
Merck
Todas as fotos(1)

Documentos Principais

Visualizar Toda a Documentação

767654

Sigma-Aldrich

cis-Dichlorobis(dimethyl sulfoxide)platinum(II)

97%

Sinônimo(s):

cis-Dichlorobis(dimethylsulfoxido)platinum(II), Pt(DMSO)2Cl2

Faça loginpara ver os preços organizacionais e de contrato
Todas as fotos(1)

About This Item

Fórmula empírica (Notação de Hill):
C4H12Cl2O2PtS2
Número CAS:
22840-91-1
Peso molecular:
422.25
Número MDL:
MFCD00061452
Código UNSPSC:
12161600
ID de substância PubChem:
329767328
NACRES:
NA.22

Nível de qualidade

100

Ensaio

97%

Formulário

solid

adequação da reação

core: platinum
reagent type: catalyst

pf

218-224 °C

cadeia de caracteres SMILES

Cl[Pt]Cl.CS(C)=O.CS(C)=O

InChI

1S/2C2H6OS.2ClH.Pt/c2*1-4(2)3;;;/h2*1-2H3;2*1H;/q;;;;+2/p-2

chave InChI

KDADQDWVKZJTDQ-UHFFFAOYSA-L

Categorias relacionadas

Descrição geral

cis-Dichlorobis(dimethyl sulfoxide)platinum(II) is a platinum complex used as a catalyst in various chemical reactions, including the methylation of polyfluorinated aryl imines and methane oxidation. It is identified as an effective C-F activation precatalyst.

Aplicação

cis-Dichlorobis(dimethyl sulfoxide)platinum(II) can be used as a:
  • Catalyst in the oleum-mediated (SO3-H2SO4) methane oxidation to form methyl bisulfate (MBS).
  • Precursor in the synthesis of cyclometalated complexes.

Pictogramas

Exclamation mark
GHS07

Palavra indicadora

Warning

Frases de perigo

H315,H319,H335

Classificações de perigo

Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

Órgãos-alvo

Respiratory system

Código de classe de armazenamento

11 - Combustible Solids

Classe de risco de água (WGK)

WGK 3

Ponto de fulgor (°F)

Not applicable

Ponto de fulgor (°C)

Not applicable

Escolha uma das versões mais recentes:

Certificados de análise (COA)

Lot/Batch Number
SHBM4371
SHBL3138
SHBH0663V
SHBC6199

Não está vendo a versão correta?

Se precisar de uma versão específica, você pode procurar um certificado específico pelo número do lote ou da remessa.

Pesquise por COA

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

Os clientes também visualizaram

Slide 1 of 5

1 of 5

Dichloro(ethylenediamine)platinum(II) 99%

Sigma-Aldrich

244929

Dichloro(ethylenediamine)platinum(II)

2,2′-Bipyrimidine 95%

Sigma-Aldrich

510556

2,2′-Bipyrimidine

Potassium tetrachloroplatinate(II) 99.99% trace metals basis

Sigma-Aldrich

323411

Potassium tetrachloroplatinate(II)

Potassium tetrachloroplatinate(II) ≥99.9% trace metals basis

Sigma-Aldrich

520853

Potassium tetrachloroplatinate(II)

Platinum(II) chloride 98%

Sigma-Aldrich

206091

Platinum(II) chloride

R S Dewoskin et al.
International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group, 9(4), 529-537 (1993-07-01)
The effects of hyperthermia (HY) on cisplatin (CDDP) nephrotoxicity and kidney metal concentrations were evaluated in female F344 rats. Rats were anaesthetized with a xylazine/ketamine mixture, heated on a water-bed for 1 h to an intraperitoneal temperature of 41.1 +/-
L Türkeri et al.
International urology and nephrology, 25(3), 259-263 (1993-01-01)
Traditional approaches for the treatment of locally advanced bladder tumours may not be sufficient enough. Neoadjuvant chemotherapy, a new modality, may be beneficial by enhancing the local and systemic control of the disease. The background of this new modality and
Osteosarcoma in adolescents and young adults: new developments and controversies. Thermal chemosensitization of cDDP-resistant cells.
A W Konings et al.
Cancer treatment and research, 62, 93-100 (1993-01-01)
H Nakagawa et al.
Journal of neuro-oncology, 16(1), 61-67 (1993-04-01)
The distribution of cis-diamminedichloroplatinum (CDDP) was studied in 23 patients undergoing surgical resection of brain tumors metastatic from lung cancer. CDDP (100 mg/m2) was administered intravenously (i.v.) or intra-arterially (IA) at the time of surgery, and various fluids and tissues
J M Bachaud et al.
Bulletin du cancer, 81(3), 212-218 (1994-03-01)
In order to enhance radiation effects in the treatment of unresectable Head and Neck squamous cell carcinoma, we initiated a phase I-II study in February 1991 with concomitant radiation and cisplatin in the treatment of resectable Head and Neck squamous
Exibir todos os documentos relacionados

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica